COMMUNIQUÉS West-GlobeNewswire

Mustang Bio Announces Key Leadership Appointments

15/03/2018 - 12:30

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a Fortress Biotech (NASDAQ: FBIO ) Company focused on the development of novel immunotherapies based on proprietary chimeric [...]

FIT Biotech Oy: FIT Biotech's Review of Operations and Financial Statement 2017 published

15/03/2018 - 11:32

FIT Biotech Oy Company announcement, March 15, 2018 at 12:30 EET FIT Biotech's Review of Operations and Financial Statement 2017 published FIT Biotech's Review of Operations and Financial Statement for the year 2017 [...]

Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting

15/03/2018 - 11:30

Data from Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Durability Data in Advanced Metastatic Melanoma BERKELEY, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation ( [...]

Vical Reports Fourth Quarter 2017 Financial and Operational Results

15/03/2018 - 11:30

SAN DIEGO, March 15, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) today reported financial results for the three months ended December 31, 2017. Net loss for the fourth quarter of 2017 was $3.7 million, [...]

BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema

15/03/2018 - 11:00

RESEARCH TRIANGLE PARK, N.C., March 15, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) announced today the dosing of the first patient into APeX-2, a Phase 3 clinical trial evaluating two dosage [...]

Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017

15/03/2018 - 11:00

NeoCart ® Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensing Agreement with MEDINET Co. Ltd. Provides Important Source of [...]

Capital Senior Living Corporation to Present at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018

15/03/2018 - 11:00

DALLAS , March 15, 2018 (GLOBE NEWSWIRE) -- Capital Senior Living Corporation (the “Company”) (NYSE: CSU ), one of the nation’s largest operators of senior living communities, today announced that management will make a [...]

BioAdaptives (OTC PINK: BDPT) Announces New Management

15/03/2018 - 11:00

LAS VEGAS, March 15, 2018 (GLOBE NEWSWIRE) -- BioAdaptives, Inc., a fully-reporting public company trading under the ticker symbol BDPT (OTC PINK:BDPT) announced that Mr. Kim D. Southworth has assumed the position of [...]

AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's disease

15/03/2018 - 10:00

First potential PET tracer for Parkinson's disease First in human study is scheduled for the second half of 2018 AC Immune's lead compound is highly selective for alpha-synuclein - a key protein in Parkinson's disease [...]

Affimed to Present Data on AFM24 at AACR Annual Meeting 2018

15/03/2018 - 09:01

Heidelberg, Germany, March 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the [...]

LIDDS: NanoZolid® with cutting edge STING agonist becomes a key project for LIDDS in immuno-oncology field

15/03/2018 - 08:30

Single intratumoral injections of a NanoZolid formulated STING agonist has been proven to achieve significant effects on tumor growth reduction and overall survival. These positive effects of the NanoZolid formulation [...]

Veritas Pharma Announces Appointment of Accomplished Business Development and Strategy Professional, Justin Kausel

15/03/2018 - 08:15

VANCOUVER, British Columbia, March 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ) ( “ Veritas ” or the “Company”) is pleased to announce that Justin Kausel has joined the [...]

Orphazyme announces Annual Report 2017

15/03/2018 - 07:34

Orphazyme A/S Company announcement No. 03/2018 Company Registration No. 32266355 Copenhagen, Denmark, March 15, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living [...]

Targovax ASA: Annual Report 2017

15/03/2018 - 07:01

On 14 March 2018, the board of directors of Targovax ASA approved the company's financial statements for 2017, which will be dealt with by the Company's annual general meeting on 11 April 2018. The company's annual [...]

Sanofi successfully prices EUR 8 billion of bond issues

15/03/2018 - 07:01

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi successfully prices EUR 8 billion of bond issues Paris, France - March 15, 2018 - Sanofi has successfully priced its offering of EUR 8 billion of notes ( [...]

Sanofi place des emprunts obligataires de 8 milliards d'euros

15/03/2018 - 07:01

Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi place des emprunts obligataires de 8 milliards d'euros Paris (France) - Le 15 mars 2018 - Sanofi a placé avec succès des émissions obligataires en [...]

Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018

15/03/2018 - 07:01

Innate Pharma to present broad and innovative portfolio in immuno-oncology at ACCR 2018 First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale [...]

ABLYNX ANNOUNCES WARRANT EXERCISE

15/03/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 15 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an [...]

AACR 2018 : Innate Pharma présente un portefeuille large et innovant en immuno-oncologie

15/03/2018 - 07:01

AACR 2018 : INNATE PHARMA PRÉSENTE UN PORTEFEUILLE LARGE ET INNOVANT EN IMMUNO-ONCOLOGIE Premières données d'activité clinique pour monalizumab en combinaison avec cetuximab Nouvelles données précliniques soutenant le [...]